D Question 1 0 pts What is the 95% confidence interval for the outcome of the Placebo group? O 1.74 +/- 0.189 O 1.74 +/- 0.225 O 1.74 +/- 3.208 O 1.74 +/- 3.822 D Question 2 0 pts When estimating the mean score for the Low Does group, how large the sample size needs to be if we want to get a margin of error of 0.1 at 95% confidence level? D Question 3 0 pts Is the difference in the mean scores between the High Does group and the Low Does group statistically significant at a 10% significance level? O Yes O No D Question 4 0 pts Is the difference in mean scores between the High Does group and the Placebo group statistically significant at a 5% significance level? O Yes O NoThe primary outcome measure is Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) chggem Week 78 CDR-SB integrates assessments from 3 domains of cognition (memory, orientation, judgment/problem-solving) and 3 domains of function (community affairs, home/hobbies, personal care). Following caregiver interview and systematic patient examination, the rater assigns a score describing the participant's current performance level in each of these domains of life functioning. Prespecied severity anchors range from none = O, questionable = 0.5, mild = 1, moderate = 2 to severe = 3 (the personal care domain omits the 0.5 score). "Sum of boxes" scoring methodology sums the score for each of the 6 domains and provides a value ranging from O to 18 that can change in increments of 0.5 or greater. Higher scores indicate greater disease severity. Mixed model for repeated measures (MMRM) analysis was used to analyze the change from baseline in CDR-SB. A positive change from baseline indicates clinical decline. The data they put together for FDA approval is based on only one of two clinical trials and the outcome measure data are as follows: Treatment Sample size Mean score Standard deviation High Does